HB 1713 (see companion bill SB 13) – OklahomaStatus: In Process
Year Introduced: 2023
prohibits pharmaceutical drug plans and pharmacy benefit managers from refusing to authorize, approve, or pay a participating provider for supplying covered physician-administered drugs to patients and requires all white-bagged drugs to meet supply chain security controls. Plan providers are prohibited from requiring a patient to self-administer an injectable drug against a provider’s recommendation and may not require patients to pay additional fees beyond cost-sharing obligations outlined in the individual’s plan. The measure also requires that providers establish a billing method based on the patient’s best interest. Any payer in violation is to be fined a minimum of $5,000 but not more than $10,000 per violation.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.